MammaPrint High 2 tumors exhibit heightened immune active state
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer
Read MoreMammaPrint & 3-year outcome of CT with/without anthracycline-ASCO 2024
Association of MammaPrint index and 3-year outcome of patients in the FLEX Registry trial with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline
Read MoreAgendia to Unveil Robust Suite of Data at 2024 ASCO
Agendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care
Read MoreGerman Gynecological Oncology Group (AGO) includes BluePrint® in Guidelines
German Gynecological Oncology Group (AGO) Recognizes BluePrint® in Breast Cancer Guidelines
Read MoreAgendia Announces New I-SPY2 Data Showcasing Ability of New Signature ImPrintTN
Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer
Read MoreAgendia Presents Data from FLEX Study at Miami Breast 2024
Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens
Read MoreAgendia Reports First Patient Enrolled in DEBRA Trial Using MammaPrint
MammaPrint 70-gene signature to aid in evaluation of de-escalation of radiation therapy in Stage I, Hormone Sensitive, HER2-Negative breast cancer
Read More
Agendia® Collaborates with National Cancer Institute, SWOG Cancer Research Network for Phase III Trial; Led by University of Michigan’s Dr. Erin Cobain GalleryAgendia® Collaborates with National Cancer Institute, SWOG Cancer Research Network for Phase III Trial; Led by University of Michigan’s Dr. Erin Cobain
Agendia® Collaborates with National Cancer Institute, SWOG Cancer Research Network for Phase III Trial; Led by University of Michigan’s Dr. Erin Cobain
SWOG S2206 will use MammaPrint® breast cancer recurrence test to examine response to immunotherapy in women with high-risk HR+ breast cancer.
Read MoreMammaPrint® approved for Reimbursement in the Netherlands
The Dutch National Healthcare Institute (ZIN) has approved MammaPrint® for inclusion in the Dutch National health insurance basic package with immediate effect.
Read MoreAgendia® Names Joyce A. O’Shaughnessy, MD as New Principal Investigator for FLEX Study
Renowned breast oncologist and clinical researcher to lead ongoing efforts to accelerate diagnostic discoveries and enable precision oncology through real-world evidence-based study platform
Read More
